SG11201610729XA - Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors - Google Patents
Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitorsInfo
- Publication number
- SG11201610729XA SG11201610729XA SG11201610729XA SG11201610729XA SG11201610729XA SG 11201610729X A SG11201610729X A SG 11201610729XA SG 11201610729X A SG11201610729X A SG 11201610729XA SG 11201610729X A SG11201610729X A SG 11201610729XA SG 11201610729X A SG11201610729X A SG 11201610729XA
- Authority
- SG
- Singapore
- Prior art keywords
- ror
- retinoid
- gamma
- inhibitors
- heterocyclic compounds
- Prior art date
Links
- 102000016978 Orphan receptors Human genes 0.000 title 1
- 108070000031 Orphan receptors Proteins 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000004492 retinoid derivatives Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014136359 | 2014-07-01 | ||
| JP2014262775 | 2014-12-25 | ||
| PCT/JP2015/069370 WO2016002968A1 (en) | 2014-07-01 | 2015-06-30 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201610729XA true SG11201610729XA (en) | 2017-01-27 |
Family
ID=53724416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610729XA SG11201610729XA (en) | 2014-07-01 | 2015-06-30 | Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US9365520B2 (es) |
| EP (1) | EP3164388A1 (es) |
| JP (1) | JP6611363B2 (es) |
| KR (1) | KR20170016987A (es) |
| CN (1) | CN106795118B (es) |
| AU (1) | AU2015285142B2 (es) |
| CA (1) | CA2954042A1 (es) |
| CL (1) | CL2016003326A1 (es) |
| CO (1) | CO2017000332A2 (es) |
| CR (1) | CR20170017A (es) |
| DO (1) | DOP2016000337A (es) |
| EA (1) | EA031262B1 (es) |
| GE (1) | GEP20196942B (es) |
| IL (1) | IL249698A0 (es) |
| MA (1) | MA40060A (es) |
| MX (1) | MX2016016870A (es) |
| PE (1) | PE20170267A1 (es) |
| PH (1) | PH12016502574A1 (es) |
| SG (1) | SG11201610729XA (es) |
| TN (1) | TN2016000567A1 (es) |
| TW (1) | TW201609751A (es) |
| UY (1) | UY36199A (es) |
| WO (1) | WO2016002968A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3018126A4 (en) * | 2013-07-03 | 2016-12-07 | Takeda Pharmaceuticals Co | HETEROCYCLIC COMPOUND |
| US9365520B2 (en) | 2014-07-01 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JPWO2016039408A1 (ja) | 2014-09-11 | 2017-06-22 | 武田薬品工業株式会社 | 複素環化合物 |
| CN105472125B (zh) * | 2015-11-16 | 2019-11-26 | 联想(北京)有限公司 | 一种信息处理方法及电子设备 |
| CR20180328A (es) | 2015-12-15 | 2018-08-09 | Astrazeneca Ab | Compuestos de isoindol |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| JP2020524660A (ja) | 2017-06-14 | 2020-08-20 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド |
| JPWO2019044940A1 (ja) * | 2017-08-31 | 2020-08-13 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
| RU2761436C1 (ru) | 2017-11-17 | 2021-12-08 | Целликс Био Прайвет Лимитед | Композиции и способы лечения нарушений со стороны органа зрения |
| US20200392107A1 (en) * | 2018-01-31 | 2020-12-17 | Toray Industries, Inc. | Cyclic amine derivative and medical use thereof |
| RU2686692C1 (ru) * | 2018-06-29 | 2019-04-30 | Федеральное Государственное Бюджетное Учреждение Науки Институт Биохимической Физики Им. Н.М. Эмануэля Российской Академии Наук (Ибхф Ран) | Применение N-(6,8,8-триметил-8,9-дигидрофуро[3,2-h]хинолин-5-ил)ацетамида в качестве средства для фототерапии псориаза и псориатического артрита |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
| WO2021228217A1 (zh) * | 2020-05-15 | 2021-11-18 | 上海辉启生物医药科技有限公司 | 可用作RORγ调节剂的苯胺类化合物 |
| CN116348096A (zh) | 2020-09-21 | 2023-06-27 | 欧克尼医疗有限公司 | 可在子宫腔内定位的装置及其治疗方法 |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250415B2 (en) | 2003-06-04 | 2007-07-31 | Bristol-Myers Squibb Company | 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors |
| WO2008121602A1 (en) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Chemical compounds |
| FR2945535B1 (fr) | 2009-05-18 | 2011-06-10 | Sanofi Aventis | Compose anticancereux et composition pharmaceutique le contenant |
| US9156837B2 (en) | 2011-07-29 | 2015-10-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP2759533B1 (en) | 2011-09-22 | 2017-08-02 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| US9108951B2 (en) | 2011-10-14 | 2015-08-18 | Bristol-Myers Squibb Company | Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors |
| IN2014CN02805A (es) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| WO2013100027A1 (ja) | 2011-12-28 | 2013-07-04 | 武田薬品工業株式会社 | 複素環化合物 |
| US9403774B2 (en) * | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| JP6280912B2 (ja) | 2013-03-14 | 2018-02-14 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3018126A4 (en) | 2013-07-03 | 2016-12-07 | Takeda Pharmaceuticals Co | HETEROCYCLIC COMPOUND |
| US10472376B2 (en) | 2013-07-03 | 2019-11-12 | Takeda Pharmaceutical Company Limited | Amide compound |
| US9365520B2 (en) | 2014-07-01 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2015
- 2015-06-30 US US14/755,439 patent/US9365520B2/en active Active
- 2015-06-30 JP JP2016575275A patent/JP6611363B2/ja not_active Expired - Fee Related
- 2015-06-30 US US15/321,609 patent/US10093629B2/en not_active Expired - Fee Related
- 2015-06-30 WO PCT/JP2015/069370 patent/WO2016002968A1/en active Application Filing
- 2015-06-30 SG SG11201610729XA patent/SG11201610729XA/en unknown
- 2015-06-30 CA CA2954042A patent/CA2954042A1/en not_active Abandoned
- 2015-06-30 AU AU2015285142A patent/AU2015285142B2/en not_active Ceased
- 2015-06-30 GE GEAP201514401A patent/GEP20196942B/en unknown
- 2015-06-30 MA MA040060A patent/MA40060A/fr unknown
- 2015-06-30 PE PE2016002802A patent/PE20170267A1/es unknown
- 2015-06-30 MX MX2016016870A patent/MX2016016870A/es unknown
- 2015-06-30 KR KR1020177001511A patent/KR20170016987A/ko unknown
- 2015-06-30 EP EP15742119.9A patent/EP3164388A1/en not_active Withdrawn
- 2015-06-30 EA EA201790112A patent/EA031262B1/ru not_active IP Right Cessation
- 2015-06-30 TN TN2016000567A patent/TN2016000567A1/en unknown
- 2015-06-30 CN CN201580046463.4A patent/CN106795118B/zh not_active Expired - Fee Related
- 2015-06-30 TW TW104121078A patent/TW201609751A/zh unknown
- 2015-06-30 CR CR20170017A patent/CR20170017A/es unknown
- 2015-07-01 UY UY0001036199A patent/UY36199A/es not_active Application Discontinuation
-
2016
- 2016-02-26 US US15/055,197 patent/US9573903B2/en not_active Expired - Fee Related
- 2016-02-26 US US15/055,108 patent/US9630924B2/en not_active Expired - Fee Related
- 2016-02-26 US US15/055,156 patent/US9650343B2/en not_active Expired - Fee Related
- 2016-12-21 IL IL249698A patent/IL249698A0/en unknown
- 2016-12-21 PH PH12016502574A patent/PH12016502574A1/en unknown
- 2016-12-26 CL CL2016003326A patent/CL2016003326A1/es unknown
- 2016-12-28 DO DO2016000337A patent/DOP2016000337A/es unknown
-
2017
- 2017-01-13 CO CONC2017/0000332A patent/CO2017000332A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249698A0 (en) | Heterocyclic compounds and their use as retinoid-related orphan receptor gamma-t inhibitors | |
| EP3226913A4 (en) | Dopamine receptor type 2 specific promoter and methods of use thereof | |
| IL252560A0 (en) | Heterocyclic derivatives and their uses | |
| IL251857A0 (en) | Amide-converted thiazoles as ror gamma t modulators | |
| IL255648B (en) | Trifluoromethyl alcohols as modulators of ror gamma t | |
| EP3209641A4 (en) | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease | |
| IL247143A0 (en) | A new use of agonistic compounds for the sigma-1 receptor | |
| EP3148986A4 (en) | Arf6 inhibitors and methods of synthesis and use thereof | |
| EP3197885A4 (en) | Heterocyclic compounds and use thereof | |
| EP3148967A4 (en) | Sulfonamide compounds and their use as stat5 inhibitors | |
| EP3191483A4 (en) | Compounds as crth2 antagonist and uses thereof | |
| PL3268356T3 (pl) | Związki heterocykliczne i sposoby ich stosowania | |
| IL254862A0 (en) | Preparations for remodeling the intercellular matrix and their use | |
| HUE050241T2 (hu) | Diarilmetilidén-piperidin származékok és alkalmazásuk delta opioid receptor agonistaként | |
| ZA201704416B (en) | Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors | |
| IL247872A0 (en) | stat5 inhibitors and their uses | |
| HUE047857T2 (hu) | Bisz(szulfonamid) származékok és felhasználásuk mPGS-inhibitorként | |
| AU2015903010A0 (en) | Heterocyclic Compounds and Methods for their Use | |
| AU2015902922A0 (en) | Heterocyclic compounds and methods for their use | |
| AU2015902886A0 (en) | Heterocyclic Compounds And Methods For Their Use | |
| AU2015902830A0 (en) | Heterocyclic compounds and methods for their use | |
| AU2015901751A0 (en) | Heterocyclic Compounds And Methods For Their Use | |
| AU2015900878A0 (en) | Heterocyclic compounds and methods for their use | |
| AU2015900077A0 (en) | Heterocyclic compounds and methods for their use | |
| AU2014901768A0 (en) | Heterocyclic compounds and use of same |